Table 1

Characteristics and disease activity at baseline of RA-BEAM for the overall baricitinib-treated and adalimumab-treated patients and for patients rescued to baricitinib between weeks 16 and 24

Overall patients in RA-BEAMPatients rescued to baricitinib
Baricitinib
4 mg (n=487)
Adalimumab
(n=330)
Baricitinib
4 mg (n=35)
Adalimumab
(n=40)
Age, years53.5 (12)52.9 (12)52.3 (12)51.9 (14)
Female, n (%)375 (77)251 (76)30 (86)31 (78)
Duration of RA,* years8.7 (8.6)8.3 (7.9)8.0 (7.8)7.0 (6.2)
ACPA positive, n (%)427 (88)295 (89)28 (80)37 (93)
RF positive, n (%)439 (90)301 (91)30 (86)38 (95)
Swollen joint count, of 6615 (8)15 (9)19 (10)19 (12)
Tender joint count, of 6823 (13)23 (14)25 (13)23 (11)
hsCRP, mg/L22 (23)22 (21)20 (20)31 (29)
ESR, mm/hour49 (26)48 (26)46 (25)56 (30)
DAS28-hsCRP5.8 (0.9)5.8 (0.9)6.0 (0.9)6.1 (0.9)
DAS28-ESR6.5 (0.9)6.4 (1.0)6.7 (1.0)6.8 (1.0)
CDAI38 (12.0)38 (13)43 (13.6)42 (13.0)
SDAI40 (12.7)40 (13.4)45 (14.2)45 (14.0)
MTX average weekly dose, mg14.9 (4.6)14.6 (4.4)15.5 (5.3)14.4 (4.2)
HAQ-DI1.57 (0.68)1.59 (0.70)1.69 (0.64)1.75 (0.64)
Patient’s assessment of pain61.8 (21.8)61.0 (22.7)67.6 (23.2)67.1 (20.9)
  • Data are mean (SD) unless otherwise stated.

  • *Time from RA diagnosis.

  • ACPA, anti-citrullinated protein antibodies; CDAI, Clinical Disease Activity Index; DAS28-ESR, disease activity score using 28-joint count with erythrocyte sedimentation rate; DAS28-hsCRP, disease activity score for 28 joints with the use of high-sensitivity C reactive protein; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate-inadequate responder; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; hsCRP, high-sensitivity C reactive protein.